PE20142098A1 - Compuestos terapeuticamente activos y sus metodos de uso - Google Patents

Compuestos terapeuticamente activos y sus metodos de uso

Info

Publication number
PE20142098A1
PE20142098A1 PE2014001077A PE2014001077A PE20142098A1 PE 20142098 A1 PE20142098 A1 PE 20142098A1 PE 2014001077 A PE2014001077 A PE 2014001077A PE 2014001077 A PE2014001077 A PE 2014001077A PE 20142098 A1 PE20142098 A1 PE 20142098A1
Authority
PE
Peru
Prior art keywords
alkyl
phenyl
methods
active compounds
therapeutically active
Prior art date
Application number
PE2014001077A
Other languages
English (en)
Spanish (es)
Inventor
Giovanni Cianchetta
Byron Delabarre
Janeta Popovici-Muller
Francesco G Salituro
Jeffrey O Saunders
Jeremy Travins
Shunqi Yan
Tao Guo
Lin Zhang
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48744984&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20142098(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of PE20142098A1 publication Critical patent/PE20142098A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2014001077A 2012-01-06 2013-01-05 Compuestos terapeuticamente activos y sus metodos de uso PE20142098A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261584214P 2012-01-06 2012-01-06

Publications (1)

Publication Number Publication Date
PE20142098A1 true PE20142098A1 (es) 2015-01-08

Family

ID=48744984

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001077A PE20142098A1 (es) 2012-01-06 2013-01-05 Compuestos terapeuticamente activos y sus metodos de uso

Country Status (39)

Country Link
US (7) US9732062B2 (enExample)
EP (4) EP4647076A3 (enExample)
JP (2) JP6411895B2 (enExample)
KR (1) KR101893112B1 (enExample)
CN (6) CN107417667B (enExample)
AR (1) AR090411A1 (enExample)
AU (2) AU2013207289B2 (enExample)
BR (1) BR112014016805B1 (enExample)
CA (1) CA2860623A1 (enExample)
CL (1) CL2014001793A1 (enExample)
CO (1) CO7030962A2 (enExample)
CR (1) CR20140377A (enExample)
CY (1) CY1120506T1 (enExample)
DK (1) DK2800743T3 (enExample)
EA (1) EA030187B1 (enExample)
EC (1) ECSP14012726A (enExample)
ES (3) ES3043635T3 (enExample)
HR (1) HRP20180844T1 (enExample)
HU (1) HUE038403T2 (enExample)
IL (1) IL233503B (enExample)
LT (1) LT2800743T (enExample)
MX (1) MX358940B (enExample)
MY (1) MY185206A (enExample)
NI (1) NI201400073A (enExample)
NO (1) NO2897546T3 (enExample)
NZ (2) NZ627096A (enExample)
PE (1) PE20142098A1 (enExample)
PH (1) PH12014501561A1 (enExample)
PL (1) PL2800743T3 (enExample)
PT (1) PT2800743T (enExample)
RS (1) RS57401B1 (enExample)
SG (2) SG11201403878QA (enExample)
SI (1) SI2800743T1 (enExample)
SM (1) SMT201800334T1 (enExample)
TR (1) TR201809228T4 (enExample)
TW (1) TWI653228B (enExample)
UA (1) UA117451C2 (enExample)
WO (1) WO2013102431A1 (enExample)
ZA (1) ZA201405163B (enExample)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102985557B (zh) 2009-03-13 2018-06-15 安吉奥斯医药品有限公司 用于细胞增殖相关病症的方法和组合物
PE20120693A1 (es) 2009-06-29 2012-07-04 Agios Pharmaceuticals Inc Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
WO2011050210A1 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
EP2525790B1 (en) 2009-10-21 2020-05-27 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
PT3406251T (pt) 2011-05-03 2024-01-24 Agios Pharmaceuticals Inc Ativadores da piruvato-cinase para utilização em terapia
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
NZ627750A (en) 2012-01-06 2016-11-25 Abide Therapeutics Inc Carbamate compounds and of making and using same
SMT201800334T1 (it) 2012-01-06 2018-09-13 Agios Pharmaceuticals Inc Composti terapeuticamente attivi e loro metodi di utilizzo
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
WO2014062511A1 (en) 2012-10-15 2014-04-24 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
CN105593215B (zh) 2013-07-11 2019-01-15 安吉奥斯医药品有限公司 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
MX375030B (es) * 2013-07-11 2025-03-06 Agios Pharmaceuticals Inc Compuestos de n,6-bis(aril o heteroaril)-1,3,5-triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento de cancer.
CN105473560B (zh) * 2013-07-11 2020-01-17 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
WO2015003355A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015010297A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
KR102316886B1 (ko) * 2013-08-02 2021-10-19 아지오스 파마슈티컬스 아이엔씨. 치료학적 활성 화합물 및 이의 사용방법
CN105916507A (zh) * 2013-08-02 2016-08-31 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
WO2015018060A1 (en) * 2013-08-09 2015-02-12 Agios Pharmaceuticals, Inc. Crystalline forms of therapeutically active compounds and use thereof
TWI651310B (zh) * 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
PH12021551647A1 (en) * 2014-03-14 2022-06-06 Agios Pharmaceuticals Inc Pharmaceutical compositions of therapeutically active compounds
SMT202100444T1 (it) * 2014-03-14 2021-09-14 Les Laboratories Servier Sas Composizioni farmaceutiche di composti terapeuticamente attivi
EP3122736A1 (en) * 2014-03-28 2017-02-01 Basf Se Diaminotriazine derivatives as herbicides
WO2015155129A1 (en) * 2014-04-07 2015-10-15 Basf Se Diaminotriazine compound
EP2930174A1 (en) * 2014-04-07 2015-10-14 Basf Se Diaminotriazine derivatives as herbicides
HUE062424T2 (hu) * 2014-09-19 2023-11-28 Forma Therapeutics Inc Piridin-2(1H)-on kinolinon származékok mint mutáns izocitrát dehidrogenáz inhibitorok
WO2016044781A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
WO2016044787A1 (en) * 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
CA2961807A1 (en) * 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
AU2015324158A1 (en) * 2014-09-29 2017-04-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3253746A1 (en) 2015-02-04 2017-12-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2016149401A2 (en) 2015-03-18 2016-09-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
EA038574B1 (ru) * 2015-04-21 2021-09-16 Форма Терапьютикс, Инк. Хинолиноновые производные пиридин-2(1h)-она и фармацевтические композиции на их основе
US10407419B2 (en) 2015-04-21 2019-09-10 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
US9624175B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
US20180134683A1 (en) * 2015-05-07 2018-05-17 Teligene Ltd. Heterocylcic compounds as idh2 inhibitors
US10450302B2 (en) 2015-05-11 2019-10-22 Lundbeck La Jolla Research Center, Inc. Methods of treating inflammation or neuropathic pain
MX384883B (es) 2015-06-11 2025-03-14 Agios Pharmaceuticals Inc Métodos para usar activadores de piruvato cinasa.
AU2016299092B2 (en) 2015-07-30 2020-08-20 Centaurus Biopharma Co., Ltd. 1, 3, 5-triazine derivative and method of using same
CN108349933A (zh) * 2015-08-05 2018-07-31 安吉奥斯医药品有限公司 制备6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二醇和6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二胺的方法
CA3002029A1 (en) 2015-10-15 2017-04-20 Celgene Corporation Combination therapy for treating malignancies
HUE067449T2 (hu) 2015-10-15 2024-10-28 Servier Lab Ivozidenib, citarabin és daunorubicin vagy idarubicin kombinációs terápa akut mielogén leukémia kezelésére
JP2018534288A (ja) 2015-10-15 2018-11-22 アジオス ファーマシューティカルズ， インコーポレイテッド 悪性腫瘍の治療のための併用療法
MD3362066T2 (ro) 2015-10-15 2022-08-31 Les Laboratoires Servier Sas Terapie combinată pentru tratamentul tumorilor maligne
JP6588647B2 (ja) * 2015-10-21 2019-10-09 ノイフォルム・ファーマシューティカルズ・インコーポレイテッドＮｅｕｆｏｒｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 血液悪性腫瘍を治療するための重水素化合物及びその組成物並びに方法
MA43374A (fr) 2015-12-04 2018-10-10 Agios Pharmaceuticals Inc Méthodes de traitement de tumeurs malignes
CN105503754B (zh) * 2015-12-11 2017-11-17 浙江大学 2‑氨基‑4‑苄基‑6‑吗啉‑1,3,5‑三嗪及其制备和应用
CN105384702B (zh) * 2015-12-11 2018-04-10 浙江大学 三取代均三嗪类化合物及其制备方法
CN105399695B (zh) * 2015-12-11 2019-04-19 浙江大学 三嗪类化合物及其制备方法和用途
US10463753B2 (en) 2016-02-19 2019-11-05 Lundbeck La Jolla Research Center, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
WO2017140758A1 (en) 2016-02-19 2017-08-24 Debiopharm International S.A. Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers
CA3015753A1 (en) 2016-02-26 2017-08-31 Celgene Corporation Idh2 inhibitors for the treatment of haematological maligancies and solid tumours
CN105820133B (zh) * 2016-03-25 2018-06-05 浙江工业大学 多取代均三嗪类化合物及其制备方法和应用
CN105753801B (zh) * 2016-03-25 2018-06-01 浙江工业大学 一种均三嗪类化合物的制备方法
KR102232614B1 (ko) * 2016-07-21 2021-03-29 난징 산홈 팔마세우티칼 컴퍼니 리미티드 이소시트레이트 탈수소효소 억제제의 화학적 화합물 및 이의 적용
WO2018026894A1 (en) 2016-08-03 2018-02-08 Celgene Corporation Methods of treatment of myelodysplastic syndrome
KR102498693B1 (ko) 2016-09-07 2023-02-10 셀진 코포레이션 정제 조성물
CN109996790B (zh) 2016-09-19 2023-05-16 H.隆德贝克有限公司 哌嗪氨基甲酸酯及其制备和使用方法
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JP7111725B2 (ja) * 2017-01-22 2022-08-02 正大天晴▲藥▼▲業▼集▲団▼股▲フン▼有限公司 １，３，５－トリアジン誘導体の塩およびその結晶、その製造方法、医薬組成物、ならびにそれらの使用
WO2018204787A1 (en) * 2017-05-05 2018-11-08 Memorial Sloan Kettering Cancer Center Methods of treatment of myeloproliferative neoplasm
EP4201399A3 (en) 2017-06-30 2023-08-09 Celgene Corporation Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
CN109265444B (zh) * 2017-07-17 2022-03-11 南京圣和药业股份有限公司 取代的三嗪类idh抑制剂的光学异构体及其应用
CN109467538A (zh) 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
UA127380C2 (uk) 2017-11-02 2023-08-02 Ле Лаборатуар Сервье Співкристали, фармацевтичні композиції на їх основі та способи лікування, які передбачають їх застосування
CN110051673B (zh) * 2018-01-19 2022-03-11 南京圣和药业股份有限公司 一种包含三嗪类idh抑制剂的药物组合物及其用途
CN110054615B (zh) * 2018-01-19 2021-06-15 南京圣和药业股份有限公司 三嗪类idh抑制剂甲磺酸盐的晶型
CN110054616B (zh) * 2018-01-19 2021-11-23 南京圣和药业股份有限公司 三嗪类idh抑制剂的制备方法
CN110054617A (zh) * 2018-01-19 2019-07-26 南京圣和药业股份有限公司 三嗪类化合物、其制备方法及用途
MA52635A (fr) 2018-05-15 2021-03-24 H Lundbeck As Inhibiteurs de magl
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
SMT202300073T1 (it) 2018-05-16 2023-05-12 Forma Therapeutics Inc Inibizione di idh-1 mutante
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
WO2020092915A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
WO2020092894A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
WO2020092906A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
CN111662271B (zh) * 2019-03-08 2023-11-14 中国药科大学 具有idh突变体抑制活性的化合物及其制备方法与应用
CN111662275B (zh) * 2019-03-08 2023-08-22 中国药科大学 苯磺酰胺类idh突变体抑制剂、其制备方法和用途
WO2020239759A1 (en) 2019-05-27 2020-12-03 Sandoz Ag Amorphous enasidenib in a stabilized form
CN114502537A (zh) * 2019-09-29 2022-05-13 贝达药业股份有限公司 突变型idh2抑制剂及其应用
KR102333854B1 (ko) 2019-10-24 2021-12-06 한국과학기술연구원 단백질 키나아제 저해 활성을 갖는 신규한 피리디닐트리아진 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
US20220401450A1 (en) 2019-11-14 2022-12-22 Celgene Corporation Pediatric formulations for treatment of cancer
WO2021214550A1 (en) 2020-04-21 2021-10-28 H. Lundbeck A/S Synthesis of a monoacylglycerol lipase inhibitor
CN111592524B (zh) * 2020-05-20 2023-11-17 温州市天聚万迅信息科技有限公司 恩西德尼的制备方法
US20240092802A1 (en) * 2020-10-06 2024-03-21 Kures, Inc. Mu-opioid receptor agonists and uses therefor
KR20230145402A (ko) * 2021-02-12 2023-10-17 르 라보레또레 쎄르비에르 치료적 활성 화합물 및 이의 사용 방법
US11865079B2 (en) 2021-02-12 2024-01-09 Servier Pharmaceuticals Llc Therapeutically active compounds and their methods of use
CN113461660B (zh) * 2021-06-11 2022-08-02 浙江大学 2,4,6-三取代-1,3,5-均三嗪类化合物及制备和应用
CN118786119A (zh) * 2022-03-15 2024-10-15 贝达药业股份有限公司 突变型idh1和idh2抑制剂及其应用
CA3246244A1 (en) * 2022-03-24 2023-09-28 A2A Pharmaceuticals, Inc. CANCER COMPOSITIONS AND TREATMENT METHODS
CN114773320A (zh) * 2022-05-29 2022-07-22 重庆医科大学 1,3,5-三嗪化合物及其制备方法和用途
CN115536637B (zh) * 2022-10-24 2025-03-18 陕西中医药大学 一种均三嗪类衍生物及其合成方法与用途
CN115819363B (zh) * 2022-12-16 2025-04-01 浙江工业大学 酮酰胺类化合物及其制备方法和应用
TW202530204A (zh) * 2023-09-27 2025-08-01 美商Ａ２Ａ製藥公司 用於治療與轉化酸性捲曲螺旋蛋白相關的癌症的方法
CN117586228A (zh) * 2023-12-01 2024-02-23 上海彩迩文生化科技有限公司 一种三嗪类药物的制备方法
CN118745158B (zh) * 2024-06-06 2026-02-03 四川省医学科学院·四川省人民医院 三嗪环衍生物、其制备方法及其应用和pdgfr激酶抑制剂

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390529A (en) 1942-02-03 1945-12-11 Ernst A H Friedheim Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds
BE754242A (fr) 1970-07-15 1971-02-01 Geigy Ag J R Diamino-s-triazines et dinitro-s-triazines
US3867383A (en) 1971-03-29 1975-02-18 Ciba Geigy Corp Monoanthranilatoanilino-s-triazines
CH606334A5 (enExample) 1974-06-21 1978-10-31 Ciba Geigy Ag
JPS58186682A (ja) 1982-04-27 1983-10-31 日本化薬株式会社 セルロ−ス又はセルロ−ス含有繊維材料の染色法
DE3512630A1 (de) 1985-04-06 1986-10-23 Hoechst Ag, 6230 Frankfurt Verfahren zum faerben oder bedrucken von cellulosefasern oder cellulosemischfasern
US5041443A (en) 1989-02-21 1991-08-20 Dainippon Pharmaceutical Co., Ltd. Medicament for treating cerebral insufficiency diseases, novel 2-(1-piperazinyl)-4-phenylcycloalkanopyrimidine derivatives, and process for the production thereof
DK0385237T3 (da) 1989-03-03 1994-07-25 Dainippon Pharmaceutical Co 2-(1-Piperazinyl)-4-phenylcycloalkanopyridinderivater, fremgangsmåde til fremstilling deraf og farmaceutisk præparat indeholdende dem
DE59106971D1 (de) 1990-07-12 1996-01-11 Ciba Geigy Ag Verfahren zur photochemischen und thermischen Stabilisierung von Polyamid-Fasermaterialien.
JPH0499768A (ja) 1990-08-17 1992-03-31 Dainippon Pharmaceut Co Ltd ４―（４―フェニルピリジン―２―イル）ピペラジン―１―オキシド誘導体
AU665238B2 (en) 1992-02-28 1995-12-21 Zenyaku Kogyo Kabushiki Kaisha S-triazine derivative and remedy for estrogen-dependent diseases containing the same as active ingredient
IL115420A0 (en) 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
FR2735127B1 (fr) 1995-06-09 1997-08-22 Pf Medicament Nouvelles piperazines heteroaromatiques utiles comme medicaments.
GB9602166D0 (en) 1996-02-02 1996-04-03 Zeneca Ltd Aminoheterocyclic derivatives
JPH09291034A (ja) 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
JP2000510866A (ja) 1996-05-20 2000-08-22 ダーウィン・ディスカバリー・リミテッド Ｔｎｆとｐｄｅ―ｉｖのインヒビターとしてのキノリンスルホンアミド
US5984882A (en) 1996-08-19 1999-11-16 Angiosonics Inc. Methods for prevention and treatment of cancer and other proliferative diseases with ultrasonic energy
EP0945446A4 (en) 1996-11-14 1999-12-08 Nissan Chemical Ind Ltd CYANOETHYLMELAMINE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME
US6399358B1 (en) 1997-03-31 2002-06-04 Thomas Jefferson University Human gene encoding human chondroitin 6-sulfotransferase
JPH11158073A (ja) * 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
UY25842A1 (es) 1998-12-16 2001-04-30 Smithkline Beecham Corp Antagonistas de receptores de il-8
WO2000075129A1 (en) 1999-06-07 2000-12-14 Shire Biochem Inc. Thiophene integrin inhibitors
DE60023920T2 (de) 1999-08-27 2006-07-20 Sugen, Inc., South San Francisco Phosphatmimetika und Verfahren zur Behandlung mit Phosphataseinhibitoren HIBITOREN
DE10196405B4 (de) 2000-07-03 2008-01-24 Kansai Paint Co., Ltd., Amagasaki Gasbarrierefolie
IL153884A0 (en) 2000-07-20 2003-07-31 Neurogen Corp Capsaicin receptor ligands
CA2450934A1 (en) 2001-06-19 2002-12-27 Marco Dodier Pyrimidine inhibitors of phosphodiesterase (pde) 7
JP4344241B2 (ja) 2001-08-17 2009-10-14 チバ ホールディング インコーポレーテッド トリアジン誘導体、およびサンスクリーンとしてのその使用
JP4753336B2 (ja) 2001-09-04 2011-08-24 日本化薬株式会社 新規アリル化合物及びその製法
WO2003037346A1 (en) * 2001-10-31 2003-05-08 Cell Therapeutics, Inc. 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer
US6878196B2 (en) 2002-01-15 2005-04-12 Fuji Photo Film Co., Ltd. Ink, ink jet recording method and azo compound
US20040067234A1 (en) 2002-07-11 2004-04-08 Paz Einat Isocitrate dehydrogenase and uses thereof
SI2256108T1 (sl) 2002-07-18 2016-05-31 Janssen Pharmaceutica N.V. Substituirani triazinski kinazni inhibitorji
JP2004107220A (ja) 2002-09-13 2004-04-08 Mitsubishi Pharma Corp ＴＮＦ−α産生抑制剤
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
US7361691B2 (en) 2002-12-02 2008-04-22 Arqule, Inc. Method of treating cancers using β-lapachone or analogs or derivatives thereof
NZ541050A (en) 2002-12-16 2010-06-25 Genmab As Human monoclonal antibodies against interleukin 8 (IL-8)
AU2004204778B2 (en) 2003-01-10 2008-05-22 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
US7358262B2 (en) 2003-01-29 2008-04-15 Whitehead Institute For Biomedical Research Identification of genotype-selective anti-tumor agents
WO2004073619A2 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
WO2004074438A2 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
EP1689722A2 (en) 2003-10-10 2006-08-16 Bayer Pharmaceuticals Corporation 4-aminopyrimidine derivatives for treatment of hyperproliferative disorders
US20070196395A1 (en) 2003-12-12 2007-08-23 Mackerell Alexander Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
CA2551524A1 (en) 2003-12-24 2005-07-21 Scios, Inc. Treatment of malignant gliomas with tgf-beta inhibitors
EP1805142A4 (en) 2004-09-23 2009-06-10 Reddy Us Therapeutics Inc PYRIDINE-BASED COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING SAME
EP1836188A1 (en) 2004-12-30 2007-09-26 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
WO2006079791A1 (en) 2005-01-25 2006-08-03 Astrazeneca Ab Chemical compounds
EP2687608B1 (en) 2005-06-08 2017-02-08 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy
ZA200801822B (en) 2005-08-26 2009-09-30 Serono Lab Pyrazine derivatives and use as p13k inhibitors
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
TW200815426A (en) 2006-06-28 2008-04-01 Astrazeneca Ab New pyridine analogues II 333
WO2008070661A1 (en) 2006-12-04 2008-06-12 Neurocrine Biosciences, Inc. Substituted pyrimidines as adenosine receptor antagonists
JP5622393B2 (ja) 2006-12-15 2014-11-12 アブラクシスバイオサイエンス リミテッド ライアビリティー カンパニー トリアジン誘導体類及びそれらの治療応用
WO2008131547A1 (en) * 2007-04-30 2008-11-06 Prometic Biosciences Inc. 'triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives'
JP2010529193A (ja) 2007-06-11 2010-08-26 ミイカナ セラピューティクス インコーポレイテッド 置換ピラゾール化合物
EA018503B1 (ru) 2007-07-20 2013-08-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Замещенные производные индазола, активные как ингибиторы киназы
WO2009027736A2 (en) * 2007-08-27 2009-03-05 Astrazeneca Ab 2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer
CL2008002998A1 (es) 2007-10-10 2009-11-20 Takeda Pharmaceuticals Co Compuestos derivados de piperazina-1-carboxamida, inhibidor de faah; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor inflamatorio o neuropatico, ansiedad y depresion.
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
JP5277685B2 (ja) 2008-03-26 2013-08-28 富士ゼロックス株式会社 電子写真感光体、画像形成装置、プロセスカートリッジ及び画像形成方法
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
CN101575408B (zh) 2008-05-09 2013-10-30 Mca技术有限公司 用作阻燃剂和光稳定剂的聚三嗪基化合物
FR2932483A1 (fr) 2008-06-13 2009-12-18 Cytomics Systems Composes utiles pour le traitement des cancers.
TW201028381A (en) 2008-07-14 2010-08-01 Shionogi & Co Pyridine derivative having ttk inhibition activity
US8685660B2 (en) 2008-09-03 2014-04-01 The Johns Hopkins University Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma
US20100144722A1 (en) 2008-09-03 2010-06-10 Dr. Reddy's Laboratories Ltd. Novel heterocyclic compounds as gata modulators
JP2010079130A (ja) 2008-09-29 2010-04-08 Fuji Xerox Co Ltd 電子写真感光体、プロセスカートリッジ、及び画像形成装置
JP2010181540A (ja) 2009-02-04 2010-08-19 Fuji Xerox Co Ltd 電子写真感光体、プロセスカートリッジ、及び画像形成装置
JP5263304B2 (ja) * 2009-02-06 2013-08-14 日本新薬株式会社 アミノピラジン誘導体及び医薬
CN102985557B (zh) 2009-03-13 2018-06-15 安吉奥斯医药品有限公司 用于细胞增殖相关病症的方法和组合物
CA2764785C (en) * 2009-06-08 2015-10-27 California Capital Equity, Llc Triazine derivatives and their therapeutical applications
US8261872B2 (en) 2009-06-08 2012-09-11 Clark Equipment Company Work machine having modular ignition switch keypad with latching output
CN102573481A (zh) 2009-06-09 2012-07-11 加利福尼亚资本权益有限责任公司 脲基苯基取代的三嗪衍生物及其治疗应用
CN102573487A (zh) 2009-06-09 2012-07-11 加利福尼亚资本权益有限责任公司 Hedgehog信号传导的吡啶基-三嗪抑制剂
WO2011005208A1 (en) 2009-07-10 2011-01-13 Milux Holding S.A. Knee joint device and method
JP5473851B2 (ja) 2009-09-30 2014-04-16 富士フイルム株式会社 高分子フィルム、位相差フィルム、偏光板及び液晶表示装置
WO2011050210A1 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
EP2525790B1 (en) 2009-10-21 2020-05-27 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
WO2011072174A1 (en) 2009-12-09 2011-06-16 Agios Pharmaceuticals, Inc. Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
US20130197106A1 (en) 2010-04-01 2013-08-01 Agios Pharmaceuticals, Inc Methods of identifying a candidate compound
CN103097340B (zh) 2010-07-16 2018-03-16 安吉奥斯医药品有限公司 治疗活性组合物及其使用方法
SG10201601507YA (en) 2010-11-29 2016-04-28 Galleon Pharmaceuticals Inc Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
TW201636330A (zh) 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102659765B (zh) 2011-12-31 2014-09-10 沈阳药科大学 嘧啶及三嗪类化合物的制备方法和应用
SMT201800334T1 (it) * 2012-01-06 2018-09-13 Agios Pharmaceuticals Inc Composti terapeuticamente attivi e loro metodi di utilizzo
NZ627750A (en) 2012-01-06 2016-11-25 Abide Therapeutics Inc Carbamate compounds and of making and using same
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
ES2698625T3 (es) 2012-01-19 2019-02-05 Agios Pharmaceuticals Inc Compuestos terapéuticamente activos y sus métodos de uso
CN104169260A (zh) 2012-03-09 2014-11-26 卡尔那生物科学株式会社 新三嗪衍生物
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015010297A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Also Published As

Publication number Publication date
EP3406608B1 (en) 2021-09-15
US20230250078A1 (en) 2023-08-10
EA201491330A1 (ru) 2015-04-30
AR090411A1 (es) 2014-11-12
AU2013207289B2 (en) 2017-09-21
TW201329054A (zh) 2013-07-16
CN108912066A (zh) 2018-11-30
CN107417667A (zh) 2017-12-01
US9656999B2 (en) 2017-05-23
AU2013207289A1 (en) 2014-07-31
CL2014001793A1 (es) 2014-11-07
US20200079755A1 (en) 2020-03-12
US20130190287A1 (en) 2013-07-25
CN107417667B (zh) 2020-04-10
IL233503A0 (en) 2014-08-31
EA030187B1 (ru) 2018-07-31
EP4647076A2 (en) 2025-11-12
US20170298045A1 (en) 2017-10-19
ES2901430T3 (es) 2022-03-22
IL233503B (en) 2018-07-31
RS57401B1 (sr) 2018-09-28
CA2860623A1 (en) 2013-07-11
US9732062B2 (en) 2017-08-15
SI2800743T1 (en) 2018-08-31
MY185206A (en) 2021-04-30
HUE038403T2 (hu) 2018-10-29
CY1120506T1 (el) 2019-07-10
PH12014501561B1 (en) 2014-10-08
SMT201800334T1 (it) 2018-09-13
JP6409081B2 (ja) 2018-10-17
PT2800743T (pt) 2018-07-04
TR201809228T4 (tr) 2018-07-23
DK2800743T3 (en) 2018-06-14
JP2017075193A (ja) 2017-04-20
HK1203942A1 (en) 2015-11-06
ES2675760T3 (es) 2018-07-12
CN108912066B (zh) 2022-06-24
KR101893112B1 (ko) 2018-08-30
ES3043635T3 (en) 2025-11-25
NO2897546T3 (enExample) 2018-01-13
NZ722582A (en) 2018-02-23
SG11201403878QA (en) 2014-08-28
BR112014016805A8 (pt) 2017-07-04
JP2015503571A (ja) 2015-02-02
US11505538B1 (en) 2022-11-22
EP3406608B8 (en) 2022-01-19
US10294215B2 (en) 2019-05-21
ECSP14012726A (es) 2016-01-29
UA117451C2 (uk) 2018-08-10
US9512107B2 (en) 2016-12-06
US20220348554A1 (en) 2022-11-03
LT2800743T (lt) 2018-06-25
EP3984997B1 (en) 2025-07-30
EP3406608A1 (en) 2018-11-28
KR20140113712A (ko) 2014-09-24
EP2800743A4 (en) 2015-08-26
NZ627096A (en) 2017-02-24
EP2800743A1 (en) 2014-11-12
CN114933585A (zh) 2022-08-23
PL2800743T3 (pl) 2018-09-28
CO7030962A2 (es) 2014-08-21
US20170044139A1 (en) 2017-02-16
AU2017265096B2 (en) 2019-08-08
AU2013207289A2 (en) 2014-07-31
BR112014016805B1 (pt) 2019-07-30
US20160318903A1 (en) 2016-11-03
MX358940B (es) 2018-09-10
PH12014501561A1 (en) 2014-10-08
CN115521264A (zh) 2022-12-27
ZA201405163B (en) 2018-05-30
NI201400073A (es) 2014-12-22
AU2017265096B9 (en) 2019-09-05
CN104114543A (zh) 2014-10-22
TWI653228B (zh) 2019-03-11
JP6411895B2 (ja) 2018-10-24
AU2017265096A1 (en) 2017-12-14
CR20140377A (es) 2014-11-13
EP2800743B1 (en) 2018-04-04
CN104114543B (zh) 2019-03-15
EP3984997A1 (en) 2022-04-20
CN115536635A (zh) 2022-12-30
HRP20180844T1 (hr) 2018-08-24
WO2013102431A1 (en) 2013-07-11
BR112014016805A2 (pt) 2017-06-13
EP4647076A3 (en) 2026-01-14
MX2014008350A (es) 2014-10-06
SG10201602862RA (en) 2016-05-30

Similar Documents

Publication Publication Date Title
PE20191541A1 (es) Composiciones y metodos para inhibir la accion de la arginasa
PE20170662A1 (es) Compuestos de aminopiridiloxipirazol
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
PE20160608A1 (es) Compuestos de quinolina selectivamente sustituida
PE20142292A1 (es) Composiciones parasiticidas que comprenden un agente activo de isoxazolina, sus metodos y usos
PE20160524A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
JOP20190142B1 (ar) مركبات 7-فينيل إيثيل أمينو-4h-بيريميدو[4، 5-d] وبيريدو[4، 3-d]-1، 3-أكسازين-2-ون كمثبطات idh1 وidh2 الطافر
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
PE20190761A1 (es) Inhibidores de procesos metabolicos celulares
PE20181288A1 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
PE20181924A1 (es) Inhibidores de la arginasa y sus aplicaciones terapeuticas
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
PE20170325A1 (es) Compuestos y composiciones como agonistas del receptor tipo toll
PE20191142A1 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
PE20140863A1 (es) Compuestos de benceno sustituidos con arilo o heteroarilo
PE20151982A1 (es) Derivados de bencimidazolona como inhibidores del bromodominio
PE20160664A1 (es) Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
PE20142359A1 (es) Procedimiento de preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas
PE20091103A1 (es) Inhibidores de la polimerasa virica
UY34027A (es) Inhibidores sustituidos de acetil-coa carboxilasa.
PE20142376A1 (es) Fluormetil-5,6-dihidro-4h-[1,3]oxazinas
PE20210478A1 (es) Compuestos heteroaromaticos como inhibidores de vanina
CO2017003969A2 (es) Derivado de isoxazol como inhibidor de isocitrato deshidrogenasa 1 mutante

Legal Events

Date Code Title Description
FG Grant, registration